Implications of MDRD for Validity of Proteinuria as a Surrogate Endpoint.

Slides:



Advertisements
Similar presentations
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Advertisements

Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Proteinuria as a Surrogate Outcome in Chronic Kidney Disease Early Diabetes – Microalbuminuria (MA) Type 2 Diabetes in American Indians Robert G Nelson,
Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,
Clinical Trial Results. org Tilman B. Drüeke, M.D.; Francesco Locatelli, M.D.; Naomi Clyne, M.D.; Kai-Uwe Eckardt, M.D.; Iain C. Macdougall, M.D.; Dimitrios.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
(IRbesartan in MicroAlbuminuria, Type 2 Diabetic Nephropathy Trial)
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Early detection, prediction and potential treatment.
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
HYPERTENSION in ADPKD Sabine Karam M.D.. Introduction  ADPKD is the most common life-threatening single-gene disease  It affects over 12 million people.
Feast or Famine: Survival and Chronic Kidney Disease Kerin Worley and Deb Gipson UNC Chapel Hill April, 2004.
HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.
Proteinuria as a Surrogate Outcome in IgA Nephropathy Ron Hogg MD Scott & White Medical Center Temple, Texas.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
Estimated GFR Based on Creatinine and Cystatin C
Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.
RENAL DISEASE IN DIABETES
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
HIV/renal studies (CHIC) Baseline renal function as predictor of HIV/renal disease progression –Death, opportunistic infection –Severe chronic kidney disease.
Proteinuria as a surrogate outcome in CKD UKPDS Rudy Bilous Middlesbrough, UK.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
A Diabetes Outcome Progression Trial
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Hypertension Control and Progression of Renal Disease
Supplemental Table A. Baseline proteinuria predicting renal outcome in multivariable Cox-Hazard model PredictorsHR95% CIp value Baseline UPE, g/day
Diabetes Prevention Program (DPP)
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
بسم الله الرحمن الرحیم.
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,
Date of download: 5/29/2016 From: The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow- up of the Modification.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
What should the Systolic BP treatment goal be in patients with CKD?
Nephrology Journal Club The SPRINT Trial Parker Gregg
Section 4: Managing progression of CKD
Urine Potassium Excretion, Kidney Failure, and Mortality in CKD
Baseline Demographic and Clinic Variables According to Office vs 24-Hour or Home BP Giuseppe Mancia, et al. Hypertension 2006;47;
Summary of Design Aim: Effect of Ramipril (up to 10mg/d) or Vit E (400 IU/d) vs its placebo on CV death, M I or stroke (primary) Design: Randomized double.
Systolic Blood Pressure Intervention Trial (SPRINT)
TNT Study: Baseline Characteristics of the Patients
The Hypertension in the Very Elderly Trial (HYVET)
Recent studies of ACE inhibition in renal disease
Management of hypertension in patients with chronic kidney disease
PREMIER: Rate of hypertension at 18 months
ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.
Hazard ratios (HR) for ESRD or death for 1-SD increase in systolic BP: Home recording vs clinic measurement BP measurement HR for each 1-SD increase.
SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,
ASPIRE CLASS 6: Interpreting Results and Writing an Abstract
GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration 
OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,
Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%
Long-term outcomes in nondiabetic chronic kidney disease
Volume 86, Issue 3, Pages (September 2014)
Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation?  Pantelis A. Sarafidis, Luis.
Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:
Baseline Characteristics, Blood Pressures, and Laboratory Values
Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:
Proteinuria and hypertensive nephrosclerosis in African Americans
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Presentation transcript:

Implications of MDRD for Validity of Proteinuria as a Surrogate Endpoint

MDRD Follow-up Randomized Trial Phase: –2 to 4 years of planned follow-up, –Mean actual follow-up, with censoring due to ESRD and death was 2.2 years –Primary outcome was iothalamate GFR slope, with iGFR measured every 4 months Long-Term Follow-up:ESRD and Death ascertained through Dec 31, 2000.

Individual Level Association

Impact of Reduction of Proteinuria in MDRD Study -- Results Interpretation: A 1 g/d initial decline in urine protein excretion was associated with a reduction in the mean slope in the period after 4 months of 0.92 ml/min/yr in Study A and of 1.32 ml/min/y in Study B Peterson JC et al, Ann Int Med 1995; 123:754

Association of GFR Slope with Initial GFR in MDRD and AASK Study Mean Initial GFR (ml/min/1.73m 2 ) Mean Initial UP (g/day) % of Variance in GFR Slope Explained MDRD Study A g/d14.0% MDRD Study B g/d13.2% AASK Study g/d17.5%

Baseline GFR <= 24.5 <= 24.5 Baseline GFR Baseline GFR > 55.5 > 55.5 Cumulative Incidence Follow-Up Time (Months ) Baseline UP ≤ 1 g/day Baseline UP > 1 g/day Individual-Level Association of Baseline UP with Incidence of ESRD Stratified by Baseline GFR (N = 1617 MDRD Enrollees)

Diet Interventions

Study A Study B Effect of Diet Interventions on % Change in Proteinuria from Baseline to 12 Months Percent Change Low Protein Usual Protein Keto Acid Low Protein Box-plots extend from 25 th to 75 th percentiles

Study B: No significant different in GFR slope or time to ESRD or Death between Very Low and Low Protein diet groups.

Implications of BP Intervention

Effect of BP Goal on Percent Change in Proteinuria from Baseline to 12 Months Percent Change > 3 UsualLowUsualLowUsual LowUsualLow < 0.3 BP Group Baseline 24 Hr UP (g/day) Box-plots extend from 25 th to 75 th percentiles

> 3 UsualLowUsualLowUsual LowUsualLow < 0.3 BP Group Baseline 24 Hr UP (g/day) Box-plots extend from 25 th to 75 th percentiles Effect of BP Goal on Absolute Change in Proteinuria from Baseline to 12 Months

Effect of Low BP Goal in Study A Change in GFR (ml/min/1.73m 2 ) Low BP Usual BP P=.01 p = 0.01 p = 0.30

MDRD: Impact of Blood Pressure Goal on Rate of Progression as a function of Proteinuria Klahr S, N Engl J Med 1994; 330:877

MDRD Long-Term Cumulative Incidence of ESRD 554/840 (66%) of Randomized Patients Reached ESRD ____ Usual Goal Low Goal Unadjusted P-value: Adjusted HR: % CI: ( ), p < 0.001

> 3g 1-3 g g <0.3 g All N=840 N=410 N=159 N=175 N=96 Hazard Ratio Baseline UP (g/day) Hazard Ratios for Low BP Goal by Level of Baseline UP (g/day) ESRD Alone ESRD/Death

MDRD Trial Effects Assessment Summary Compar- ison Δ UP 3-Yr Slope Chronic Slope Long-term ESRD or Death Low vs. Usual Protein Low Protein (small) NULL Low Protein Equivocal Very Low vs. Low Protein NULL Low vs. Usual BP Low BP (big) NULLLow BP Low vs. Usual BP Effect Modification by Baseline UP: General consistency between effect on absolute Δ UP and effects on slope & clinical endpoints.

THANK YOU

Extra Slides

MDRD: Long Term Outcomes - 2 Sarnak et al, Ann Int Med 2005; 142:342

MDRD: Cumulative Variance of GFR Slopes Explained by Covariates Hunsicker LG et al. Kidney Int 1997; 51:

624/840 (74%) of Randomized Patients Reached ESRD or Death Low BP Usual BP Unadjusted P-value: Adjusted HR: % CI: ( ), p = MDRD Long-Term Cumulative Incidence of ESRD/Death

MDRD: Cumulative Variance of GFR Slopes Explained by Covariates Hunsicker LG et al. Kidney Int 1997; 51:

UP > 3g/day UP 1-3g/day UP g/day UP < 0.3 g/day Percent Change Effect of Low Protein Diet on Change in Proteinuria